Navigation Links
Amsterdam Molecular Therapeutics to Appoint Alexander Ribbink to Supervisory Board
Date:3/19/2008

AMSTERDAM, March 20 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today announced that AMT's Supervisory Board has decided to propose Alexander Ribbink to be appointed to the Supervisory Board at its Annual General Meeting of shareholders on April 16, 2008. Mr. Ribbink is Chief Operating Officer of TomTom (Euronext Amsterdam: TOM2), and has been instrumental in building TomTom into the world's largest portable navigation solutions provider.

Mr. Ribbink, who joined TomTom in 2003, spent 11 years with Unilever, specializing in consumer marketing and general management, becoming vice-president for brand development for one of the company's largest Dutch food subsidiaries. He later managed a key European business unit for Mars, Inc.

Further to a plan of rotation that aims to build a fully independent Supervisory Board in the course of 2008, AMT expects to propose several other independent candidates to replace current non-independent members. Earlier this year, AMT announced the nomination of Mr. Philippe van Holle, Head of Celgene Europe (NASDAQ: CELG), to its Supervisory Board.

AMT's AGM is scheduled for April 16, 10:30 a.m., and will take place at the Rosarium, Amsterdam, The Netherlands.

About Amsterdam Molecular Therapeutics

AMT has a unique gene therapy platform that to date appears to circumvent many if not all of the obstacles that have prevented gene therapy from becoming a mainstay of clinical medicine. Using adeno-associated viral (AAV) vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate what is probably the first stable and scalable AAV production platform. As such, AMT's proprietary platform holds tremendous promise for thousands of rare (orphan) diseases that are caused by one faulty gene. AMT currently has a product pipeline with six products at different stages of development.

Certain statements in this press release are "forward-looking statements" including those that refer to management's plans and expectations for future operations, prospects and financial condition. Words such as "strategy," "expects," "plans," "anticipates," "believes," "will," "continues," "estimates," "intends," "projects," "goals," "targets" and other words of similar meaning are intended to identify such forward-looking statements. Such statements are based on the current expectations of the management of Amsterdam Molecular Therapeutics only. Undue reliance should not be placed on these statements because, by their nature, they are subject to known and unknown risks and can be affected by factors that are beyond the control of AMT. Actual results could differ materially from current expectations due to a number of factors and uncertainties affecting AMT's business, including, but not limited to, the timely commencement and success of AMT's clinical trials and research endeavors, delays in receiving U.S. Food and Drug Administration or other regulatory approvals (i.e. EMEA, Health Canada), market acceptance of AMT's products, effectiveness of AMT's marketing and sales efforts, development of competing therapies and/or technologies, the terms of any future strategic alliances, the need for additional capital, the inability to obtain, or meet, conditions imposed for required governmental and regulatory approvals and consents. AMT expressly disclaims any intent or obligation to update these forward-looking statements except as required by law. For a more detailed description of the risk factors and uncertainties affecting AMT, refer to the prospectus of AMT's initial public offering on June 20, 2007, and AMT's public announcements made from time to time.


'/>"/>
SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Amsterdam Molecular Therapeutics Reports Full Year Results 2007
2. Amsterdam Molecular Therapeutics to Appoint Philippe van Holle (Celgene) to Supervisory Board
3. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
4. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
5. Society for Biomolecular Sciences Announces 2008 Conference Speaker Line-up
6. WaferGen to Present at the Cambridge Health Institutes Fifth Annual Molecular Diagnostics Partnerships in Personalized Medicine Conference
7. NIST team proves bridge from conventional to molecular electronics possible
8. AcroMetrix Signs Development and Supply Agreement With Beckman Coulter Inc. for Molecular Quality Control Standards
9. Center for Molecular Medicine Partners with AviaraDx to Offer New Cancer Tests to Aid Physicians in Personalizing Treatment
10. Center for Molecular Medicine Among First to Offer New FDA-Approved Test to Aid in Treatment of Prostate Cancer
11. Molecular Diagnostics Leader AdvanDx Taps Former Dako Executive Vice President to Lead Global Sales and Marketing Expansion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... ... August 15, 2017 , ... The Conference Forum and The ... through a series of upcoming panels and events. The partnership culminates with the ... Hotel in New York City. , “With our experience in producing the Immuno-Oncology 360° ...
(Date:8/14/2017)... ... August 14, 2017 , ... Opal Kelly, a leading ... PCI Express, announced the release of SYZYGY™, a new open standard for connecting ... for a compact, low cost, low pin-count, high-performance connectivity solution between FPGAs and ...
(Date:8/11/2017)... ... August 11, 2017 , ... Algenist continues to disrupt the ... collagen like never before. , Collagen is the key structural element skin needs ... Liquid Collagen™, which include: , First to market with ...
(Date:8/10/2017)... ... August 09, 2017 , ... The era of using extracellular ... The team at Capricor Therapeutics, Inc. utilized a cardiosphere-derived stem-like cell culturing process ... Dr. Travis Antes, head of analytical development at Capricor Therapeutics Inc., will be ...
Breaking Biology Technology:
(Date:4/13/2017)... 13, 2017 According to a new market research ... Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and ... is expected to grow from USD 14.30 Billion in 2017 to USD ... 17.3%. ... MarketsandMarkets Logo ...
(Date:4/11/2017)... , April 11, 2017 No two ... researchers at the New York University Tandon School ... Engineering have found that partial similarities between prints ... used in mobile phones and other electronic devices ... The vulnerability lies in the fact that ...
(Date:4/5/2017)...  The Allen Institute for Cell Science today announces ... portal and dynamic digital window into the human cell. ... application of deep learning to create predictive models of ... a growing suite of powerful tools. The Allen Cell ... publicly available resources created and shared by the Allen ...
Breaking Biology News(10 mins):